登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688502 证券简称：茂莱光学 公告编号：2025-095 及已支付发行费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 2025年12月18日，南京茂莱光学科技股份有限公司（以下简称"公司"）召开第四届董事会审计委员会 第十五次会议、第四届董事会第十七次会议，审议通过了《关于使用可转换公司债券募集资金置换预先 投入募投项目及已支付发行费用的自筹资金的议案》，同意公司使用募集资金置换预先已投入募投项目 及已支付发行费用的自筹资金，置换资金总额为人民币595.9898万元（不含税）。 ● 本次募集资金置换时间距募集资金到账日未超过6个月，符合相关法律法规的要求。现将具体情况公 告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意南京茂莱光学科技股份有限公司向不特定对象发行可转换公司债 券注册的批复》（证监许可〔2025〕2433号）同意注册，公司向不特定对象发行56,250.00万元的可转换 公司债券，期限为6年， ...

Core Points - The company will not distribute profits or increase share capital from reserves for the first half of 2025 [3] - The board of directors and supervisory board confirm the authenticity, accuracy, and completeness of the report [1][5] - The half-year report has not been audited [2] Company Overview - The company is Zhejiang Dongya Pharmaceutical Co., Ltd. [6] - The fourth board meeting was held on August 28, 2025, with all directors present [6][8] - The supervisory board meeting also took place on the same day, with all supervisors present [13][16] Financial Data - The actual amount raised from the convertible bonds was RMB 69 million, with a net amount of RMB 68.018 million after deducting fees [21] - As of June 30, 2025, the company had invested RMB 29 million in financial products, with RMB 20 million remaining unexpired [25] Important Matters - The company has not experienced significant changes in its operating conditions during the reporting period [4] - The company has not changed its convertible bond fundraising investment projects during the reporting period [28] Asset Impairment - The company has recognized an asset impairment provision totaling RMB 32.0236 million for the first half of 2025 [38] - This includes a bad debt provision of RMB 0.0877 million for accounts receivable and a provision of RMB 31.9804 million for inventory [39][41] - The impairment provision is in accordance with accounting standards and reflects the company's asset situation accurately [42]